Plain-English translation of NCT07002034 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a single injection of RE104 can help reduce depression and anxiety symptoms in people who are struggling emotionally because of a serious medical diagnosis like cancer, ALS, multiple sclerosis, Parkinson's disease, or pulmonary fibrosis. Researchers want to see if this medication can ease the emotional burden that often comes with a serious health condition. You would receive just one injection as part of the study.
When people are diagnosed with serious illnesses, many experience depression and anxiety as a result. Current treatments take time to work or may not work well for everyone. This trial is exploring whether this medication could offer faster relief with just a single dose.
You likely qualify if…
You likely don't qualify if…
You would receive a single injection under the skin (either a lower dose or higher dose of the medication, assigned randomly). The study is designed to be short and straightforward—researchers will check how you are doing and whether your depression or anxiety symptoms improve. You may need to complete some questionnaires and visits to assess your mood and safety, but this is a single-dose study so there is no ongoing medication to take after the injection.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States